Skip to content

Remedium Bio

Dose-adjustable gene therapy for obesity and osteoarthritis

Raised to date

$1.5M

of $10M offered across 1 Form D filing

Still open
$8.5M
Investors
1
Last filed
May 18, 2026

About

Remedium Bio is a clinical-stage biotechnology company developing gene therapies for chronic diseases with large patient populations. Its Prometheus adjustable gene therapy platform is designed to replace repeated subcutaneously administered protein treatments with a single, dose-adjustable injection, using established AAV and lipid nanoparticle delivery vectors. Its pipeline spans endocrinology (obesity and Type 2 diabetes), neurology (ischemic stroke), and rheumatology (an FGF18 gene therapy for osteoarthritis intended to regenerate cartilage). The company was founded in 2020 and is based in the Boston area, with the Form D filed from Needham, Massachusetts.

Dose adjustability — the Prometheus platform is built so a single gene therapy injection can be titrated up or down after administration, which is the central limitation of conventional one-and-done gene therapy, and it does so using clinically validated targets and established AAV/LNP vectors rather than novel delivery chemistry.

Funding

  • EquityFiled May 18, 2026Form D
    $1.5M/ $10M

Product

Prometheus adjustable gene therapy platform

Gene therapy platform

A gene therapy platform delivering therapeutic genes via adeno-associated virus (AAV) and lipid nanoparticle (LNP) vectors in a single injection whose dose can be adjusted, intended to replace ongoing subcutaneous protein therapy with one durable, localized treatment.

  • Single-injection, dose-adjustable gene therapy
  • Uses established AAV and lipid nanoparticle delivery vectors
  • Localized and durable administration replacing repeated subcutaneous protein dosing

Built for

Patients with chronic high-prevalence conditions — obesity and Type 2 diabetes, osteoarthritis, and ischemic stroke — reached through clinicians, health systems, and pharmaceutical partners

People on file